Approval · Notice of Compliance 19274 · 2017
CAPRELSA: Notice of Compliance 19274
Issued May 8, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19274
- Date
- May 8, 2017
- Company
- Sanofi Genzyme, A Division Of Sanofi-Aventis Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the product monograph in response to an advisement letter pertaining to new adverse events
Products in this notice
Medicinal ingredients
- VANDETANIB 100 MG per MG
- VANDETANIB 300 MG per MG